NATURAL KILLER/T-CELL LYMPHOMA, NASAL AND NASAL-TYPE
Clinical trials for NATURAL KILLER/T-CELL LYMPHOMA, NASAL AND NASAL-TYPE explained in plain language.
Never miss a new study
Get alerted when new NATURAL KILLER/T-CELL LYMPHOMA, NASAL AND NASAL-TYPE trials appear
Sign up with your email to follow new studies for NATURAL KILLER/T-CELL LYMPHOMA, NASAL AND NASAL-TYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New trial aims to find best treatment order for rare lymphoma
Disease control Recruiting nowThis study is for people with early-stage natural killer/T-cell lymphoma, a rare and aggressive cancer often linked to EBV. It compares three different sequences of chemotherapy, immunotherapy, and radiation to see which one keeps the cancer from coming back for at least two year…
Matched conditions: NATURAL KILLER/T-CELL LYMPHOMA, NASAL AND NASAL-TYPE
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 22, 2026 12:09 UTC
-
New drug combo shows promise for rare, aggressive blood cancer
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug sintilimab to standard chemotherapy can help people with a rare and aggressive type of lymphoma (NK/T-cell lymphoma) that has spread. About 84 newly diagnosed patients will be randomly assigned to receive either the combinati…
Matched conditions: NATURAL KILLER/T-CELL LYMPHOMA, NASAL AND NASAL-TYPE
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC